---
title: "MedHallu: A Comprehensive Benchmark for Detecting Medical Hallucinations in Large Language Models"
summary: "MedHallu: ì˜ë£Œ LLM í™˜ê° ê²€ì¶œì„ ìœ„í•œ í¬ê´„ì  ë²¤ì¹˜ë§ˆí¬"
categories: ["AI Generated", "ğŸ¤— Daily Papers"]
tags: ["Natural Language Processing", "Large Language Models", "ğŸ¢ University of Texas at Austin",]
showSummary: true
date: 2025-02-20
draft: false
---

<br>

{{< keywordList >}}
{{< keyword icon="fingerprint" >}} 2502.14302 {{< /keyword >}}
{{< keyword icon="writer" >}} Shrey Pandit et el. {{< /keyword >}}
 
{{< keyword >}} ğŸ¤— 2025-02-24 {{< /keyword >}}
 
{{< /keywordList >}}

{{< button href="https://arxiv.org/abs/2502.14302" target="_self" >}}
â†— arXiv
{{< /button >}}
{{< button href="https://huggingface.co/papers/2502.14302" target="_self" >}}
â†— Hugging Face
{{< /button >}}
{{< button href="https://paperswithcode.com/paper/medhallu-a-comprehensive-benchmark-for" target="_self" >}}
â†— Papers with Code
{{< /button >}}




### TL;DR


{{< lead >}}

ì˜ë£Œ ë¶„ì•¼ì—ì„œ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)ì˜ ì •í™•ì„±ì€ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ LLMì€ ì‚¬ì‹¤ì´ ì•„ë‹Œ ê·¸ëŸ´ë“¯í•œ ì •ë³´ë¥¼ ìƒì„±í•˜ëŠ” 'í™˜ê°' í˜„ìƒì„ ë³´ì…ë‹ˆë‹¤. ì´ëŠ” ì˜ë£Œ ë¶„ì•¼ì—ì„œ ì‹¬ê°í•œ ìœ„í—˜ì„ ì´ˆë˜í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.  ê¸°ì¡´ì˜ í™˜ê° ê²€ì¶œ ë²¤ì¹˜ë§ˆí¬ëŠ” ì˜ë£Œ ë„ë©”ì¸ íŠ¹ìœ ì˜ ì–´ë ¤ì›€ì„ ì¶©ë¶„íˆ ë°˜ì˜í•˜ì§€ ëª»í–ˆìŠµë‹ˆë‹¤.

ë³¸ ì—°êµ¬ëŠ” ì˜ë£Œ í™˜ê° ê²€ì¶œì„ ìœ„í•œ ìƒˆë¡œìš´ ë²¤ì¹˜ë§ˆí¬ì¸ MedHalluë¥¼ ì œì‹œí•©ë‹ˆë‹¤.  MedHalluëŠ” PubMedQA ë°ì´í„°ì…‹ì„ ê¸°ë°˜ìœ¼ë¡œ 10,000ê°œì˜ ê³ í’ˆì§ˆ ì§ˆì˜ì‘ë‹µ ìŒì„ í¬í•¨í•˜ë©°, ì œì–´ëœ íŒŒì´í”„ë¼ì¸ì„ í†µí•´ ì²´ê³„ì ìœ¼ë¡œ í™˜ê° ë‹µë³€ì„ ìƒì„±í•©ë‹ˆë‹¤.  ì‹¤í—˜ ê²°ê³¼, ìµœì²¨ë‹¨ LLMë„ ì–´ë ¤ìš´ í™˜ê° ê²€ì¶œ ê³¼ì œì—ì„œ ë‚®ì€ F1 ì ìˆ˜ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ, ë„ë©”ì¸ íŠ¹í™” ì§€ì‹ê³¼ "í™•ì‹ í•˜ì§€ ëª»í•¨" ë‹µë³€ ì˜µì…˜ì„ ì¶”ê°€í•¨ìœ¼ë¡œì¨ ì •í™•ë„ì™€ F1 ì ìˆ˜ê°€ í¬ê²Œ í–¥ìƒë˜ì—ˆìŠµë‹ˆë‹¤.

{{< /lead >}}


#### Key Takeaways

{{< alert "star" >}}
{{< typeit speed=10 lifeLike=true >}} MedHalluëŠ” ì˜ë£Œ í™˜ê° ê²€ì¶œì„ ìœ„í•œ ìµœì´ˆì˜ ë²¤ì¹˜ë§ˆí¬ ë°ì´í„°ì…‹ì…ë‹ˆë‹¤. {{< /typeit >}}
{{< /alert >}}

{{< alert "star" >}}
{{< typeit speed=10 startDelay=1000 lifeLike=true >}} ìµœì²¨ë‹¨ LLMë„ ì–´ë ¤ìš´ ì˜ë£Œ í™˜ê° ê²€ì¶œ ê³¼ì œë¥¼ í•´ê²°í•˜ëŠ” ë° ì–´ë ¤ì›€ì„ ê²ªìŠµë‹ˆë‹¤. {{< /typeit >}}
{{< /alert >}}

{{< alert "star" >}}
{{< typeit speed=10 startDelay=2000 lifeLike=true >}} ë„ë©”ì¸ íŠ¹í™” ì§€ì‹ê³¼ "í™•ì‹ í•˜ì§€ ëª»í•¨" ì˜µì…˜ì„ ì¶”ê°€í•˜ë©´ ì •í™•ë„ì™€ F1 ì ìˆ˜ê°€ í–¥ìƒë©ë‹ˆë‹¤. {{< /typeit >}}
{{< /alert >}}

#### Why does it matter?
**MedHallu**ëŠ” ì˜ë£Œ ë¶„ì•¼ì—ì„œ **ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)**ì˜ í™˜ê°(hallucination) ë¬¸ì œë¥¼ í•´ê²°í•˜ê¸° ìœ„í•œ ì¤‘ìš”í•œ **ë²¤ì¹˜ë§ˆí¬**ë¥¼ ì œê³µí•©ë‹ˆë‹¤.  ì´ ë…¼ë¬¸ì€ ì˜ë£Œ í™˜ê° ê²€ì¶œì˜ ì–´ë ¤ì›€ì„ ë³´ì—¬ì£¼ê³ ,  **ë„ë©”ì¸ íŠ¹í™” ì§€ì‹**ì„ í†µí•©í•˜ê³  **"í™•ì‹ í•˜ì§€ ëª»í•¨" ì˜µì…˜**ì„ ë„ì…í•˜ì—¬ ì •í™•ë„ë¥¼ í–¥ìƒì‹œí‚¤ëŠ” ë°©ë²•ì„ ì œì‹œí•©ë‹ˆë‹¤. ì´ëŠ” **ì˜ë£Œ AI ì•ˆì „**ì„ ë†’ì´ê³  **LLM ê¸°ë°˜ ì˜ë£Œ ì• í”Œë¦¬ì¼€ì´ì…˜**ì˜ ì‹ ë¢°ì„±ì„ ë†’ì´ëŠ” ë° ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤.  í–¥í›„ ì—°êµ¬ë¥¼ ìœ„í•œ ìƒˆë¡œìš´ ë°©í–¥ì„ ì œì‹œí•˜ë©°, ì˜ë£Œ ìì—°ì–´ ì²˜ë¦¬(NLP) ë¶„ì•¼ì— ì¤‘ìš”í•œ ê¸°ì—¬ë¥¼ í•©ë‹ˆë‹¤.

------
#### Visual Insights



![](https://arxiv.org/html/2502.14302/x1.png)

> ğŸ”¼ ê·¸ë¦¼ 1ì€ ì˜ë£Œ í™˜ê° ê²€ì¶œì˜ í•œ ì˜ˆì‹œë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì§ˆë¬¸ê³¼ ë‹µë³€ì´ ì£¼ì–´ì§€ê³ , ëª¨ë¸ì´ ë‹µë³€ì´ ì˜í•™ì ìœ¼ë¡œ ì •í™•í•œì§€ ë˜ëŠ” í™˜ê°(ì˜ëª»ëœ ì •ë³´)ì¸ì§€ë¥¼ íŒë‹¨í•´ì•¼ í•©ë‹ˆë‹¤.  ë¶€ë¡ Kì—ëŠ” í™˜ê° ê²€ì¶œ ì‘ì—…ì— ì‚¬ìš©ëœ ìì„¸í•œ í”„ë¡¬í”„íŠ¸ê°€ ë‚˜ì™€ ìˆìŠµë‹ˆë‹¤.  ì´ ì˜ˆì‹œëŠ” ì˜ë£Œ ë¶„ì•¼ì—ì„œì˜ ì˜ëª»ëœ ì •ë³´ ìƒì„±ì˜ ìœ„í—˜ì„±ì„ ê°•ì¡°í•˜ë©°, MedHallu ë²¤ì¹˜ë§ˆí¬ê°€ í•´ê²°í•˜ê³ ì í•˜ëŠ” ë¬¸ì œë¥¼ ëª…í™•íˆ ë³´ì—¬ì¤ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Figure 1: An example of medical hallucination detection. The detailed prompt used for the hallucination detection task is presented in Appendix K.
> </details>





{{< table-caption >}}
| Hallucination Category | Description | Example |
|---|---|---|
| Misinterpretation of Question | Misunderstanding the question, leading to an irrelevant response. | #Question#: Does high-dose vitamin C therapy improve survival rates in patients with sepsis? <br> #Answer#: Vitamin C is water-soluble vitamin that plays a role in immune function and collagen synthesis. |
| Incomplete Information | Stays on-topic but omits the essential details needed to fully answer the question. | #Question#: How does penicillin treat strep throat? <br> #Answer#: Penicillin kills bacteria. |
| Mechanism and Pathway Misattribution | False attribution of biological mechanisms, molecular pathways, or disease processes that contradicts established medical knowledge. | #Question#: What is the primary mechanism of action of aspirin in reducing inflammation? <br> #Answer#: Aspirin primarily reduces inflammation by blocking calcium channels in immune cells, which prevents the release of histamine and directly suppresses T-cell activation. |
| Methodological and Evidence Fabrication | Inventing false research methods, statistical data, or specific clinical outcomes. | #Question#: What is the success rate of ACL reconstruction surgery? <br> #Answer#: Recent clinical trials using quantum-guided surgical technique showed 99.7% success rate across 10,543 patients with zero complications when using gold-infused synthetic grafts. |{{< /table-caption >}}

> ğŸ”¼ MedHallu ë°ì´í„°ì…‹ ìƒì„±ì— ì‚¬ìš©ëœ ì˜í•™ì  í™˜ê°ì˜ ì¢…ë¥˜ë¥¼ ë³´ì—¬ì£¼ëŠ” í‘œì…ë‹ˆë‹¤. KnowHallu ë²¤ì¹˜ë§ˆí¬(Zhang et al., 2024a)ì—ì„œ ìˆ˜ì • ë° ì˜í•™ ë¶„ì•¼ì— ë§ê²Œ ì¡°ì •ëœ ë²”ì£¼ë“¤ì„ ê¸°ë°˜ìœ¼ë¡œ í•©ë‹ˆë‹¤.  ê° ë²”ì£¼ëŠ” ì§ˆë¬¸ ì˜¤í•´, ì •ë³´ ë¶€ì¡±, ë©”ì»¤ë‹ˆì¦˜ ë° ê²½ë¡œ ì˜¤ë¥˜ ì§€ì •, ë°©ë²•ë¡  ë° ì¦ê±° ì¡°ì‘ ë“± í™˜ê° ìœ í˜•ì— ëŒ€í•œ ì„¤ëª…ê³¼ ì˜ˆì‹œë¥¼ í¬í•¨í•©ë‹ˆë‹¤. ë¶€ë¡ Dì—ëŠ” ìì„¸í•œ ë‚´ìš©ì´ ìˆìŠµë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 1: Categories of medical hallucinations used to generate the MedHalu dataset. Adapted from the KnowHallu benchmark (Zhang etÂ al., 2024a) with revised categories tailored to the medical domain (Appendix D).
> </details>





### In-depth insights


#### MedHallu Dataset
MedHallu ë°ì´í„°ì…‹ì€ ì˜ë£Œ ë¶„ì•¼ì˜ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM) í™˜ê°(hallucination) ê²€ì¶œì„ ìœ„í•œ **ì¢…í•©ì ì¸ ë²¤ì¹˜ë§ˆí¬**ë¥¼ ì œê³µí•˜ëŠ” í•µì‹¬ ìš”ì†Œì…ë‹ˆë‹¤. **10,000ê°œì˜ ê³ í’ˆì§ˆ ì§ˆì˜ì‘ë‹µ ìŒ**ìœ¼ë¡œ êµ¬ì„±ë˜ì–´ ìˆìœ¼ë©°, PubMedQA ë°ì´í„°ì…‹ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ì—¬ ì²´ê³„ì ì¸ íŒŒì´í”„ë¼ì¸ì„ í†µí•´ ìƒì„±ëœ í™˜ê° ì‘ë‹µë“¤ì„ í¬í•¨í•©ë‹ˆë‹¤. **ë‚œì´ë„(ì‰¬ì›€, ì¤‘ê°„, ì–´ë ¤ì›€)**ì— ë”°ë¼ ê³„ì¸µí™”ë˜ì–´ ìˆì–´ ëª¨ë¸ì˜ ì„±ëŠ¥ì„ ì„¸ë¶„í™”í•˜ì—¬ í‰ê°€í•  ìˆ˜ ìˆê²Œ í•©ë‹ˆë‹¤. ë˜í•œ, í™˜ê° ìœ í˜•(ì§ˆë¬¸ ì˜¤í•´, ì •ë³´ ëˆ„ë½, ë©”ì»¤ë‹ˆì¦˜ ì˜¤ë¥˜, ì¦ê±° ì¡°ì‘)ì„ ë¶„ë¥˜í•˜ì—¬ ë‹¤ì–‘í•œ ìœ í˜•ì˜ í™˜ê°ì— ëŒ€í•œ ëª¨ë¸ì˜ ì·¨ì•½ì„±ì„ ë¶„ì„í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ íŠ¹ì§•ë“¤ì€ MedHallu ë°ì´í„°ì…‹ì´ **ì˜ë£Œ LLMì˜ ì‹ ë¢°ì„±ê³¼ ì•ˆì „ì„± í–¥ìƒ**ì— í¬ê²Œ ê¸°ì—¬í•  ìˆ˜ ìˆìŒì„ ì‹œì‚¬í•©ë‹ˆë‹¤. íŠ¹íˆ, ì˜ë£Œ ë¶„ì•¼ì˜ íŠ¹ìˆ˜ì„±ì„ ê³ ë ¤í•œ ë°ì´í„°ì…‹ êµ¬ì„±ì€ ê¸°ì¡´ì˜ ì¼ë°˜ì ì¸ í™˜ê° ê²€ì¶œ ë²¤ì¹˜ë§ˆí¬ì˜ í•œê³„ë¥¼ ê·¹ë³µí•˜ê³ , **ì˜ë£Œ í™˜ê²½ì— íŠ¹í™”ëœ LLM ê°œë°œ ë° í‰ê°€**ì— ì¤‘ìš”í•œ ì—­í• ì„ í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.

#### Hallucination Types
ì˜ë£Œ í™˜ê²½ì—ì„œì˜ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)ì˜ í™˜ê° í˜„ìƒ ìœ í˜•ì„ ë¶„ì„í•˜ëŠ” ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. **í™˜ê°ì˜ ìœ í˜•ì„ ëª…í™•íˆ êµ¬ë¶„í•˜ëŠ” ê²ƒì€ í™˜ê°ì„ ê°ì§€í•˜ê³  ì™„í™”í•˜ê¸° ìœ„í•œ ì „ëµì„ ê°œë°œí•˜ëŠ” ë° í•„ìˆ˜ì ì…ë‹ˆë‹¤.** ì´ëŠ” í™˜ê°ì˜ ê·¼ë³¸ ì›ì¸ê³¼ ë©”ì»¤ë‹ˆì¦˜ì— ëŒ€í•œ ì´í•´ë¥¼ í•„ìš”ë¡œ í•©ë‹ˆë‹¤.  ì˜ˆë¥¼ ë“¤ì–´, ì§ˆë¬¸ ì˜¤í•´ëŠ” ëª¨ë¸ì´ ì§ˆë¬¸ì˜ ì˜ë„ë¥¼ ì˜ëª» í•´ì„í•˜ì—¬ ì‚¬ì‹¤ê³¼ ë‹¤ë¥¸ ë‹µë³€ì„ ìƒì„±í•˜ëŠ” ê²½ìš°ë¥¼ ë§í•©ë‹ˆë‹¤. ë°˜ë©´, ë¶ˆì™„ì „í•œ ì •ë³´ëŠ” ëª¨ë¸ì´ ê´€ë ¨ ì •ë³´ì˜ ì¼ë¶€ë§Œ ì œê³µí•˜ê±°ë‚˜ ì¤‘ìš”í•œ ì„¸ë¶€ ì •ë³´ë¥¼ ëˆ„ë½í•˜ì—¬ ë¶€ì •í™•í•œ ì‘ë‹µì„ ë§Œë“œëŠ” ê²½ìš°ì…ë‹ˆë‹¤. ë©”ì»¤ë‹ˆì¦˜ ë° ê²½ë¡œ ì˜¤ë¥˜ ì§€ì •ì€ ìƒë¬¼í•™ì  ë©”ì»¤ë‹ˆì¦˜, ë¶„ì ê²½ë¡œ ë˜ëŠ” ì§ˆë³‘ ê³¼ì •ì— ëŒ€í•œ ì˜ëª»ëœ ì„¤ëª…ì„ í¬í•¨í•˜ë©°, ë°©ë²•ë¡ ì  ë° ì¦ê±° ì¡°ì‘ì€ í—ˆìœ„ ì—°êµ¬ ë°©ë²•, í†µê³„ ë°ì´í„° ë˜ëŠ” íŠ¹ì • ì„ìƒ ê²°ê³¼ë¥¼ ë§Œë“¤ì–´ë‚´ëŠ” ê²½ìš°ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. **ê° ìœ í˜•ì€ ëª¨ë¸ì˜ í•œê³„ì™€ í›ˆë ¨ ë°ì´í„°ì˜ í¸í–¥ì„±ì„ ë°˜ì˜í•˜ë©°, ì´ëŸ¬í•œ ì´í•´ëŠ” ë³´ë‹¤ ì •í™•í•˜ê³  ì•ˆì „í•œ ì˜ë£Œ LLM ê°œë°œì— ì¤‘ìš”í•œ ì—­í• ì„ í•©ë‹ˆë‹¤.** ë”°ë¼ì„œ, í™˜ê° ìœ í˜•ì— ëŒ€í•œ ì‹¬ì¸µì ì¸ ì—°êµ¬ëŠ” ì˜ë£Œ í™˜ê²½ì—ì„œ LLMì˜ ì‹ ë¢°ì„±ê³¼ ì•ˆì „ì„±ì„ í–¥ìƒì‹œí‚¤ëŠ” ë° í¬ê²Œ ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤.  **ì˜ë£Œ í™˜ê²½ì˜ íŠ¹ìˆ˜ì„±ì„ ê³ ë ¤í•œ í™˜ê° ìœ í˜• ë¶„ë¥˜ ì²´ê³„ë¥¼ ê°œë°œí•˜ê³ , ê° ìœ í˜•ì— ëŒ€í•œ êµ¬ì²´ì ì¸ ì˜ˆì‹œ ë° í•´ê²° ë°©ì•ˆì„ ì œì‹œí•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•œ ì—°êµ¬ ë°©í–¥**ì…ë‹ˆë‹¤.

#### LLM Evaluation
LLM í‰ê°€ëŠ” **ëª¨ë¸ì˜ ì„±ëŠ¥ê³¼ ì•ˆì „ì„±ì„ ì¸¡ì •í•˜ëŠ” ë° í•„ìˆ˜ì **ì…ë‹ˆë‹¤.  ê¸°ì¡´ì˜ ë°©ì‹ë“¤ì€ ì¢…ì¢… ë‹¨ìˆœ ì •í™•ë„ì—ë§Œ ì´ˆì ì„ ë§ì¶°, **í™˜ê°(hallucination)ê³¼ ê°™ì€ ì¤‘ìš”í•œ ë¬¸ì œì ë“¤ì„ ê°„ê³¼**í•˜ëŠ” ê²½í–¥ì´ ìˆì—ˆìŠµë‹ˆë‹¤.  **ì˜ë£Œ ë¶„ì•¼ì—ì„œëŠ” íŠ¹íˆ í™˜ê°ìœ¼ë¡œ ì¸í•œ ìœ„í—˜ì„±ì´ í¬ê¸° ë•Œë¬¸ì—**, ì˜ë£Œ ì§€ì‹ì— íŠ¹í™”ëœ ë°ì´í„°ì…‹ì„ ì‚¬ìš©í•œ í‰ê°€ê°€ ì¤‘ìš”í•©ë‹ˆë‹¤.  **ì˜ë£Œ ì „ë¬¸ê°€ì˜ ê²€í† ë¥¼ ê±°ì¹œ ê³ í’ˆì§ˆ ë°ì´í„°ì…‹**ì„ í™œìš©í•˜ê³ , **ë‹¤ì–‘í•œ ì¸¡ë©´(ì •í™•ì„±, ì•ˆì „ì„±, íš¨ìœ¨ì„± ë“±)ì„ ì¢…í•©ì ìœ¼ë¡œ ê³ ë ¤**í•˜ëŠ” í‰ê°€ ì§€í‘œë¥¼ ê°œë°œí•´ì•¼ í•©ë‹ˆë‹¤.  **ë‹¨ìˆœ ì •í™•ë„ ë¿ ì•„ë‹ˆë¼, í™˜ê° ë°œìƒë¥ , ì‹ ë¢°ë„, ì„¤ëª… ê°€ëŠ¥ì„± ë“±ì„ í•¨ê»˜ í‰ê°€**í•˜ì—¬ ì‹¤ì œ ì˜ë£Œ í˜„ì¥ ì ìš© ê°€ëŠ¥ì„±ì„ ë³´ë‹¤ ì •í™•í•˜ê²Œ íŒë‹¨í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.  ë˜í•œ, **ì˜ë£Œ ì „ë¬¸ê°€ì˜ í”¼ë“œë°±ì„ ì§€ì†ì ìœ¼ë¡œ ë°˜ì˜**í•˜ì—¬ LLM í‰ê°€ ë°©ë²•ì„ ê°œì„ í•´ë‚˜ê°€ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤.  ê¶ê·¹ì ìœ¼ë¡œ **ì¸ê°„ì˜ ê°ë…ê³¼ í˜‘ë ¥ì„ í†µí•´ ì•ˆì „í•˜ê³  ì‹ ë¢°í•  ìˆ˜ ìˆëŠ” ì˜ë£Œ LLMì„ ê°œë°œ**í•˜ëŠ” ë° ê¸°ì—¬í•´ì•¼ í•©ë‹ˆë‹¤.

#### Knowledge Impact
ë³¸ ë…¼ë¬¸ì—ì„œ "ì§€ì‹ì˜ ì˜í–¥"ì— ëŒ€í•œ ì‹¬ì¸µì ì¸ ë¶„ì„ì€ **ì˜ë£Œ ë¶„ì•¼ì˜ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM) ì„±ëŠ¥ í–¥ìƒ**ì— ì¤‘ì ì„ ë‘¡ë‹ˆë‹¤.  **ì „ë¬¸ ì§€ì‹ì„ LLMì— ì œê³µ**í•˜ë©´ ì˜ë£Œ í™˜ê° ê²€ì¶œ ì„±ëŠ¥ì´ í¬ê²Œ í–¥ìƒë˜ëŠ” ê²ƒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. íŠ¹íˆ ì¼ë°˜ì ì¸ LLMì€ ì˜ë£Œ ì „ë¬¸ LLMë³´ë‹¤ ì§€ì‹ í™œìš© ì¸¡ë©´ì—ì„œ ë” í° ì„±ëŠ¥ í–¥ìƒì„ ë³´ì…ë‹ˆë‹¤. ì´ëŠ” ì¼ë°˜ LLMì´ ì˜ë£Œ ì „ë¬¸ ì§€ì‹ì— ëŒ€í•œ ì‚¬ì „ í•™ìŠµì´ ë¶€ì¡±í•˜ê¸° ë•Œë¬¸ì—, ì¶”ê°€ì ì¸ ì§€ì‹ì´ ì£¼ì–´ì¡Œì„ ë•Œ ë” í° í•™ìŠµ íš¨ê³¼ë¥¼ ë³´ì´ëŠ” ê²ƒìœ¼ë¡œ í•´ì„í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.  **ì˜ë£Œ ì „ë¬¸ ì§€ì‹ì˜ í†µí•©**ì€ ëª¨ë¸ì˜ ì •í™•ì„±ê³¼ ì¬í˜„ìœ¨ì„ ë†’ì´ëŠ” ë° ì¤‘ìš”í•œ ì—­í• ì„ í•˜ë©°, íŠ¹íˆ ì–´ë ¤ìš´ í™˜ê° ì‚¬ë¡€ì— ëŒ€í•œ íŒë³„ ëŠ¥ë ¥ì„ í–¥ìƒì‹œí‚µë‹ˆë‹¤.  í•˜ì§€ë§Œ, ëª¨ë¸ í¬ê¸°ì™€ ì§€ì‹ í™œìš© ê°„ ìƒê´€ê´€ê³„ëŠ” ë‹¨ìˆœí•˜ì§€ ì•Šì•„, ëª¨ë¸ ê·œëª¨ì— ë”°ë¼ ì§€ì‹ í™œìš©ì˜ íš¨ê³¼ê°€ ë‹¤ë¥´ê²Œ ë‚˜íƒ€ë‚  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ì‹œì‚¬í•©ë‹ˆë‹¤.  **"not sure" ì˜µì…˜ ì¶”ê°€**ëŠ” ëª¨ë¸ì˜ ì •ë°€ë„ í–¥ìƒì— ê¸°ì—¬í•˜ë©°, íŠ¹íˆ ì˜ë£Œ ë¶„ì•¼ì˜ ë†’ì€ ì‹ ë¢°ë„ ìš”êµ¬ì‚¬í•­ì„ ì¶©ì¡±í•˜ëŠ” ë° ì¤‘ìš”í•œ ì—­í• ì„ í•©ë‹ˆë‹¤.

#### Future Work
ë³¸ ë…¼ë¬¸ì€ ì˜ë£Œ í™˜ìì˜ ì•ˆì „ê³¼ ì„ìƒì  ì˜ì‚¬ê²°ì •ì— ìˆì–´ì„œ **ì˜ë£Œ í™˜ê°(medical hallucination)** ë¬¸ì œë¥¼ í•´ê²°í•˜ê¸° ìœ„í•œ ì¤‘ìš”í•œ ì²«ê±¸ìŒì„ ì œì‹œí•©ë‹ˆë‹¤.  í•˜ì§€ë§Œ, ì•„ì§ í•´ê²°í•´ì•¼ í•  ê³¼ì œë“¤ì´ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. ë¯¸ë˜ ì—°êµ¬ ë°©í–¥ìœ¼ë¡œëŠ” **ë‹¤ì–‘í•œ ê³ í’ˆì§ˆ ì˜ë£Œ ë°ì´í„°ì…‹ í™•ë³´**ë¥¼ í†µí•œ ëª¨ë¸ì˜ ì¼ë°˜í™” ì„±ëŠ¥ í–¥ìƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤.  **ì˜ë£Œ ì „ë¬¸ê°€ì˜ ì§€ì‹ì„ íš¨ê³¼ì ìœ¼ë¡œ í†µí•©**í•˜ëŠ” ë°©ë²•ì— ëŒ€í•œ ì—°êµ¬ë„ í•„ìš”í•˜ë©°, **ë‹¤ì–‘í•œ ì˜ë£Œ ë¶„ì•¼ì— ëŒ€í•œ ì „ë¬¸ì ì¸ ì§€ì‹ì„ ê°–ì¶˜ ëª¨ë¸ ê°œë°œ** ë° **ë‹¤ì–‘í•œ ì˜ë£Œ í™˜ê° ìœ í˜•ì„ ë”ìš± ì •êµí•˜ê²Œ ë¶„ë¥˜í•˜ê³  ê²€ì¶œí•˜ëŠ” ê¸°ìˆ  ê°œë°œ**ë„ í•„ìˆ˜ì ì…ë‹ˆë‹¤. ë˜í•œ, **ëª¨ë¸ì˜ ì‹ ë¢°ì„±ì„ í‰ê°€í•˜ëŠ” ìƒˆë¡œìš´ ì§€í‘œ ê°œë°œ**ê³¼ **ì¸ê³µì§€ëŠ¥ ëª¨ë¸ì˜ ì•ˆì „ì„± ë° ìœ¤ë¦¬ì ì¸ ì‚¬ìš©**ì— ëŒ€í•œ ì—°êµ¬ê°€ ë³‘í–‰ë˜ì–´ì•¼ í•  ê²ƒì…ë‹ˆë‹¤.  íŠ¹íˆ, ì˜ë£Œ ë¶„ì•¼ì˜ íŠ¹ìˆ˜ì„±ì„ ê³ ë ¤í•œ **ì„¤ëª… ê°€ëŠ¥í•œ ì¸ê³µì§€ëŠ¥(explainable AI)** ê¸°ìˆ  ê°œë°œì„ í†µí•´ ì˜ë£Œ í˜„ì¥ì—ì„œì˜ ì‹ ë¢°ë„ë¥¼ ë†’ì´ëŠ” ë° ì§‘ì¤‘í•´ì•¼ í•  ê²ƒì…ë‹ˆë‹¤.  **ì˜ë£Œ í™˜ê° ë¬¸ì œì— ëŒ€í•œ ì‹¬ì¸µì ì¸ ì´í•´**ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í•œ ì´ëŸ¬í•œ ë¯¸ë˜ ì—°êµ¬ëŠ” ì˜ë£Œ ì¸ê³µì§€ëŠ¥ ê¸°ìˆ ì˜ ë°œì „ê³¼ ì•ˆì „í•œ í™œìš©ì— í¬ê²Œ ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤.


### More visual insights

<details>
<summary>More on figures
</summary>


![](https://arxiv.org/html/2502.14302/x2.png)

> ğŸ”¼ ê·¸ë¦¼ 2ëŠ” MedHallu ì˜ë£Œ í™˜ê° ë‹µë³€ ìƒì„± íŒŒì´í”„ë¼ì¸ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. PubMedQA ë°ì´í„°ì…‹ì˜ ê° ì§ˆë¬¸-ë‹µë³€ ìŒì€ í™˜ê° ë‹µë³€ì„ ìƒì„±í•˜ê¸° ìœ„í•´ ë‹¤ìŒ ë‹¨ê³„ë¥¼ ê±°ì¹©ë‹ˆë‹¤. 1ë‹¨ê³„ëŠ” í›„ë³´ ìƒì„± ë‹¨ê³„ë¡œ, ì§ˆë¬¸, ê´€ë ¨ ì§€ì‹, ì •ë‹µì´ ì£¼ì–´ì§€ë©´ LLMì€ ë„¤ ê°€ì§€ í™˜ê° ìœ í˜• ì¤‘ í•˜ë‚˜ì— ë§ì¶° í™˜ê° ë‹µë³€ì„ ìƒì„±í•˜ë¼ëŠ” í”„ë¡¬í”„íŠ¸ë¥¼ ë°›ìŠµë‹ˆë‹¤. 2ë‹¨ê³„ëŠ” ë“±ê¸‰ ë° í•„í„°ë§ ë‹¨ê³„ë¡œ, ìƒì„±ëœ ë‹µë³€ì€ í’ˆì§ˆ ë° ì •í™•ì„± ê²€ì‚¬ë¥¼ ê±°ì¹˜ë©°, í•„í„°ë§ ê²°ê³¼ì— ë”°ë¼ ì–´ë ¤ì›€(hard), ì¤‘ê°„(medium), ì‰¬ì›€(easy) ë˜ëŠ” ì‹¤íŒ¨(failed)ë¡œ ë¶„ë¥˜ë©ë‹ˆë‹¤. 3ë‹¨ê³„ëŠ” ì‹¤íŒ¨í•œ ìƒì„±ì„ ìˆ˜ì •í•˜ëŠ” ë‹¨ê³„ë¡œ, ì‹¤íŒ¨í•œ ë‹µë³€ì€ TextGrad (Yuksekgonul et al., 2024)ë¥¼ ì‚¬ìš©í•˜ì—¬ ìµœì í™”ë˜ê³  ë‹¤ì‹œ í•„í„°ë§ë©ë‹ˆë‹¤. ë‹¤ì‹œ ì‹¤íŒ¨í•˜ë©´ LLMì€ ìƒˆë¡œìš´ ë‹µë³€ì„ ìƒì„±í•˜ë¼ëŠ” í”„ë¡¬í”„íŠ¸ë¥¼ ë°›ìŠµë‹ˆë‹¤ (ì¬ìƒì„±). 4ë‹¨ê³„ëŠ” ëŒ€ì²´ ë‹¨ê³„ë¡œ, 4ë²ˆì˜ ì¬ìƒì„± ì‹œë„ í›„ì—ë„ ì ê²© ë‹µë³€ì´ ë‚˜íƒ€ë‚˜ì§€ ì•Šìœ¼ë©´ ì •ë‹µê³¼ ê°€ì¥ ìœ ì‚¬í•œ ë‹µë³€ì´ ì‰¬ìš´ í™˜ê° ì‚¬ë¡€ë¡œ ì„ íƒë©ë‹ˆë‹¤. í™˜ê° ìƒì„± ì‘ì—…ì— ì‚¬ìš©ëœ ìì„¸í•œ í”„ë¡¬í”„íŠ¸ëŠ” ë¶€ë¡ Kì— ë‚˜ì™€ ìˆìŠµë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Figure 2: MedHallu medical hallucinated answer generation pipeline. Each question-answer pair from the PubMedQA dataset undergoes the following steps to generate a hallucinated answer: (1) Candidate Generation: Given a question, relevant knowledge, and ground truth answer, the LLM is prompted to generate a hallucinated answer adhering to one of four hallucination types. (2) Grading & Filtering: Generated answers undergo quality and correctness checks, being labeled as hard, medium, easy, or failed based on filtering results. (3) Refining Failed Generation: Failed answers are optimized using TextGradÂ Yuksekgonul etÂ al. (2024) and re-filtered. If they fail again, the LLM is re-prompted to generate new answers (Regeneration). (4) Fallback: If no qualified answers emerge after four regeneration attempts, the answer most similar to the ground truth is selected as an easy hallucinated example. The detailed prompt used for hallucination generation task is presented in the AppendixÂ K.
> </details>



![](https://arxiv.org/html/2502.14302/x3.png)

> ğŸ”¼ ê·¸ë¦¼ 3ì€ MedHallu ë°ì´í„°ì…‹ì˜ í†µê³„ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.  ë°ì´í„°ì…‹ì€ ì˜ë£Œ í™˜ê°ì˜ ë„¤ ê°€ì§€ ë²”ì£¼(í‘œ 1 ì°¸ì¡°)ì™€ ë‚œì´ë„(ì‰¬ì›€, ì¤‘ê°„, ì–´ë ¤ì›€)ë³„ë¡œ ë¶„ë¥˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê° ë²”ì£¼ì™€ ë‚œì´ë„ì— ì†í•œ ìƒ˜í”Œ ìˆ˜ë¥¼ ì‹œê°ì ìœ¼ë¡œ ë³´ì—¬ì£¼ëŠ” ì°¨íŠ¸ í˜•íƒœë¡œ í‘œí˜„ë˜ì–´, ë°ì´í„°ì…‹ì˜ êµ¬ì„±ê³¼ ê° í™˜ê° ìœ í˜• ë° ë‚œì´ë„ì˜ ë¶„í¬ë¥¼ í•œëˆˆì— íŒŒì•…í•  ìˆ˜ ìˆë„ë¡ í•©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Figure 3: Statistics of the MedHallu dataset categorized by four categories of hallucinations (see Table 1 for detailed definitions) and levels of difficulty (easy, medium, hard).
> </details>



![](https://arxiv.org/html/2502.14302/x4.png)

> ğŸ”¼ ê·¸ë¦¼ 4ëŠ” MedHallu ë°ì´í„°ì…‹ì—ì„œ ë‹¤ì–‘í•œ ìœ í˜•ì˜ í™˜ê°ì— ëŒ€í•œ Qwen2-7B-Instruct ëª¨ë¸ì˜ ê²€ì¶œ ì •í™•ë„ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ê° í™˜ê° ìœ í˜•(ì§ˆë¬¸ ì˜¤í•´, ë¶ˆì™„ì „í•œ ì •ë³´, ë©”ì»¤ë‹ˆì¦˜/ê²½ë¡œ ì˜¤ë¥˜ ì§€ì •, ë°©ë²•ë¡ ì  ë° ì¦ê±° ì¡°ì‘)ì— ëŒ€í•œ ì •í™•ë„ë¥¼ ì‹œê°ì ìœ¼ë¡œ ë¹„êµí•˜ì—¬ ì–´ë–¤ ìœ í˜•ì˜ í™˜ê°ì´ ë” ì‰½ê²Œ ë˜ëŠ” ì–´ë µê²Œ ê°ì§€ë˜ëŠ”ì§€ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ëŠ” ëª¨ë¸ì˜ í™˜ê° ê°ì§€ ì„±ëŠ¥ì„ í‰ê°€í•˜ëŠ” ë° ìœ ìš©í•œ ì •ë³´ë¥¼ ì œê³µí•©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Figure 4: Detection accuracy of different hallucination categories on MedHallu, evaluated using Qwen2-7B-Instruct as the discriminator.
> </details>



</details>




<details>
<summary>More on tables
</summary>


{{< table-caption >}}
| Metric | Mean (fooled) | Mean (not fooled) | P-value |
|---|---|---|---| 
| Cosine similarity | 0.715 | 0.696 | 0.004 |
| Euclidean distance | 0.714 | 0.750 | 0.002 |
| Rouge1-F1 | 0.358 | 0.319 | 0.002 |{{< /table-caption >}}
> ğŸ”¼ í‘œ 2ëŠ” MedHallu ë°ì´í„°ì…‹(10,000ê°œ ìƒ˜í”Œ)ì„ ì‚¬ìš©í•˜ì—¬ ì§€ì‹ ìœ ë¬´ì— ë”°ë¥¸ ë‹¤ì–‘í•œ LLMsì˜ ì„±ëŠ¥ì„ ë¹„êµí•œ í‘œì…ë‹ˆë‹¤.  ëŒ€ë¶€ë¶„ì˜ ì§€í‘œì—ì„œ ì¼ë°˜ì ì¸ LLMsê°€ ì˜ë£Œ í™˜ê° íƒì§€ ì‘ì—…ì—ì„œ ì˜ë£Œ ì „ìš©ìœ¼ë¡œ ë¯¸ì„¸ ì¡°ì •ëœ LLMsë³´ë‹¤ ë” ë‚˜ì€ ì„±ëŠ¥ì„ ë³´ì—¬ì¤ë‹ˆë‹¤.  'ì „ì²´ ì •ë°€ë„(Overall P)'ëŠ” ì •ë°€ë„ë¥¼ ë‚˜íƒ€ë‚´ë©°,  'ì§€ì‹ ì°¨ì´(Î” Knowledge)'ëŠ” ì§€ì‹ì´ ì œê³µë˜ì—ˆì„ ë•Œ ì „ì²´ F1 ì ìˆ˜ì˜ ë³€í™”ëŸ‰ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.  ì¼ë°˜ LLMê³¼ ë¯¸ì„¸ ì¡°ì •ëœ ì˜ë£Œ LLMì˜ í¬ê¸°ë¥¼ ê³µì •í•˜ê²Œ ë¹„êµí•˜ê¸° ìœ„í•´ GPT-4oë¥¼ ì œì™¸í•˜ê³  í‰ê· ì„ ê³„ì‚°í–ˆìŠµë‹ˆë‹¤. ìì„¸í•œ ì‹¤í—˜ ë‚´ìš©ì€ ë¶€ë¡ Eë¥¼ ì°¸ì¡°í•˜ì‹­ì‹œì˜¤.
> <details>
> <summary>read the caption</summary>
> Table 2: Performance comparison of different LLMs with and without knowledge on MedHallu (10,000 samples). General LLMs perform better than medically fine-tuned LLMs in the task of Medical Hallucination across most metrics. â€œOverall Pâ€ denotes precision, and â€œÎ”Î”\Deltaroman_Î” Knowledgeâ€ is the performance change in overall F1 when knowledge is provided. âˆ—We exclude GPT-4o while calculating the average to have a fair comparison of model sizes for general vs. fine-tuned LLMs. Additional experimental details can be found in Appendix E.
> </details>

{{< table-caption >}}
| Model | F1<sub>NS</sub> | P<sub>NS</sub> | F1<sub>R</sub> | P<sub>R</sub> | Response% |
|---|---|---|---|---|---| 
| GPT-4o-mini | 66.6 | 66.8 | 60.7 | 77.2 | 98.4 |
| Gemma-2-2b-it | 57.1 | 59.9 | 55.3 | 54.1 | 82.7 |
| Llama-3.2-3B-Instruct | 58.1 | 68.7 | 49.9 | 63.3 | 85.9 |
| Qwen2.5-3B-Instruct | 65.2 | 67.2 | 60.6 | 50.2 | 65.7 |
| BioMistral-7B | 56.5 | 50.5 | 57.0 | 51.3 | 99.2 |
| Qwen2.5-7B-Instruct | 69.3 | **94.6** | 55.3 | 73.7 | 47.5 |
| OpenBioLLM-Llama3-8B | 48.8 | 48.4 | 48.4 | 56.3 | 99.7 |
| Llama-3.1-8B-UltraMedical | 58.5 | 49.1 | 61.9 | 56.4 | 69.7 |
| DeepSeek-R1-Llama-8B | 66.0 | 56.9 | 51.4 | 61.7 | 98.1 |
| Llama-3.1-8B-Instruct | 51.7 | 90.4 | 52.2 | **86.0** | 98.2 |
| Gemma-2-9b-it | 61.4 | 85.5 | 51.5 | 71.5 | 37.6 |
| Qwen2.5-14B-Instruct | 76.2 | 82.9 | 61.9 | 76.5 | 27.9 |
| GPT-4o | **79.5** | 79.6 | **73.7** | 72.4 | 33.9 |{{< /table-caption >}}
> ğŸ”¼ ì´ í‘œëŠ” 5.3ì ˆì—ì„œ ìƒì„±ëœ í´ëŸ¬ìŠ¤í„°ì™€ ì‹¤ì œ ì •ë‹µ ê°„ì˜ í‰ê·  ìœ ì‚¬ë„ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.  ê²€ì¶œ LLMì„ ì†ì´ëŠ” ìƒ˜í”Œ(ì¦‰, ê²€ì¶œí•˜ê¸° ì–´ë ¤ìš´ í™˜ê°)ì„ í¬í•¨í•˜ëŠ” í´ëŸ¬ìŠ¤í„°ëŠ” ì‹¤ì œ ì •ë‹µê³¼ ìƒë‹¹íˆ ê°€ê¹ìŠµë‹ˆë‹¤.  ìœ ì‚¬ë„ëŠ” ì½”ì‚¬ì¸ ìœ ì‚¬ë„, ìœ í´ë¦¬ë“œ ê±°ë¦¬, Rouge-1 F1 ì ìˆ˜ ì„¸ ê°€ì§€ ì§€í‘œë¡œ ì¸¡ì •ë˜ì–´, ì–´ë ¤ìš´ í™˜ê°ì¼ìˆ˜ë¡ ì‹¤ì œ ì •ë‹µê³¼ ì˜ë¯¸ì ìœ¼ë¡œ ë” ê°€ê¹ë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ëŠ” ì–´ë ¤ìš´ í™˜ê°ì´ ì‹¤ì œ ì •ë‹µê³¼ ì˜ë¯¸ì ìœ¼ë¡œ ìœ ì‚¬í•˜ì§€ë§Œ ì‚¬ì‹¤ê³¼ëŠ” ë‹¤ë¥¸ ì„¸ë¶€ ì‚¬í•­ì„ í¬í•¨í•˜ê³  ìˆìŒì„ ì‹œì‚¬í•©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 3: The average similarity between the clusters generated in Section 5.3 and the ground truth samples. Clusters containing samples that fool detection LLMs (i.e., hallucinations that are more challenging to detect) are notably closer to the ground truth.
> </details>

{{< table-caption >}}
| Model | F1<sub>NS</sub> | P<sub>NS</sub> | F1<sub>R</sub> | P<sub>R</sub> | Response % |
|---|---|---|---|---|---| 
| GPT-4o-mini | 83.6 | 77.7 | 84.1 | 82.0 | 100.0 |
| Gemma-2-2b-it | 75.5 | 67.2 | 71.5 | 67.4 | 89.2 |
| Llama-3.2-3B-Instruct | 76.8 | 67.9 | 73.4 | 55.5 | 90.8 |
| Qwen2.5-3B-Instruct | 69.2 | 47.0 | 67.6 | 49.8 | 94.2 |
| BioMistral-7B | 67.2 | 53.2 | 64.8 | 54.5 | 98.7 |
| Qwen2.5-7B-Instruct | 88.6 | 91.6 | 83.9 | 85.0 | 74.6 |
| OpenBioLLM-Llama3-8B | 40.2 | 58.9 | 42.4 | 55.5 | 99.4 |
| Llama-3.1-8B-UltraMedical | 72.9 | 56.1 | 77.3 | 73.4 | 95.1 |
| DeepSeek-R1-Llama-8B | 68.9 | 85.4 | 81.2 | 83.4 | 95.2 |
| Llama-3.1-8B-Instruct | 77.7 | **92.7** | 80.0 | **88.6** | 99.7 |
| Gemma-2-9b-it | 84.7 | 83.4 | 83.8 | 78.6 | 90.3 |
| Qwen2.5-14B-Instruct | **88.8** | 92.5 | 85.2 | 84.3 | 87.0 |
| GPT-4o | 84.9 | 78.3 | **87.7** | 88.3 | 95.2 |{{< /table-caption >}}
> ğŸ”¼ í‘œ 4ëŠ” ëª¨ë¸ì´ 'ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤' ì˜µì…˜ì„ ì‚¬ìš©í•  ìˆ˜ ìˆì„ ë•Œì™€ ë‹µë³€ì„ í•´ì•¼ í•  ë•Œì˜ ì„±ëŠ¥ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. F1NSì™€ PNS(ì •ë°€ë„)ëŠ” 'ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤' ì˜µì…˜ì´ ìˆì„ ë•Œì˜ ì„±ëŠ¥ì„ ë‚˜íƒ€ë‚´ê³ , F1Rê³¼ PR(ì •ë°€ë„)ëŠ” ë‹µë³€í•´ì•¼ í•  ë•Œì˜ ì„±ëŠ¥ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. Response%ëŠ” 'ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤' ì˜µì…˜ì´ ìˆì–´ë„ 'ì˜ˆ' ë˜ëŠ” 'ì•„ë‹ˆì˜¤'ë¡œ ë‹µë³€í•œ ì§ˆë¬¸ì˜ ë¹„ìœ¨ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.  ì¦‰, 'ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤' ì˜µì…˜ì´ ìˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ëª¨ë¸ì´ í™•ì‹ ì„ ê°€ì§€ê³  ë‹µë³€ì„ í–ˆëŠ”ì§€, ì•„ë‹ˆë©´ 'ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤' ì˜µì…˜ì„ ì–¼ë§ˆë‚˜ í™œìš©í–ˆëŠ”ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ì§€í‘œì…ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 4: F1NS and PNS (Precision) represent performance with the â€œNot Sureâ€ option, while F1R and PR (Precision) represent performance when required to answer. Response% represents the percentage of questions answered with â€œYesâ€ or â€œNoâ€ even when the â€œNot Sureâ€ option is available.
> </details>

{{< table-caption >}}
| Computational Budget and Infrastructure Details while generating MedHallu |
|---|---| 
| **Primary Model:** | Qwen2.5-14B (14B parameters) |
| **Computation Time:** | 26.5 hours |
| **GPU Hardware:** | 4 x NVIDIA RTX A6000 (48,685 MiB RAM each) |
| **Additional Models:** | Gemma2-9B (9B parameters), Qwen2.5-7B (7B parameters), GPT4omini (used for correctness check) |
| **Dataset Size:** | 10,000 samples |{{< /table-caption >}}
> ğŸ”¼ í‘œ 5ëŠ” 'í™•ì‹ í•˜ì§€ ëª»í•¨' ì˜µì…˜ì„ ì‚¬ìš©í–ˆì„ ë•Œì˜ F1 ì ìˆ˜(F1NS)ì™€ ì •ë°€ë„(PNS), ê·¸ë¦¬ê³  ë‹µë³€í•´ì•¼ í•  ê²½ìš°ì˜ F1 ì ìˆ˜(F1R)ì™€ ì •ë°€ë„(PR)ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. Response%ëŠ” 'ì˜ˆ' ë˜ëŠ” 'ì•„ë‹ˆì˜¤'ë¡œ ë‹µë³€í•´ì•¼ í•˜ëŠ” ì§ˆë¬¸ì˜ ë¹„ìœ¨ì„ ë‚˜íƒ€ë‚´ë©°, 'í™•ì‹ í•˜ì§€ ëª»í•¨' ì˜µì…˜ì´ ìˆë”ë¼ë„ 'ì˜ˆ' ë˜ëŠ” 'ì•„ë‹ˆì˜¤'ë¡œë§Œ ë‹µë³€í•œ ì§ˆë¬¸ì˜ ë¹„ìœ¨ì„ ì˜ë¯¸í•©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 5:  F1NS and PNS (Precision) represent performance with the â€œNot Sureâ€ option, while F1R and PR represent performance when required to answer. Response% represents the percentage of questions answered with â€œYesâ€ or â€œNoâ€ even when the â€œNot Sureâ€ option is available.
> </details>

{{< table-caption >}}
| Pre-trained Models and huggingface names |
|---|---| 
| `m42-health/Llama3-Med42-8B` |
| `OpenMeditron/Meditron3-8B` |
| `aaditya/OpenBioLLM-Llama3-8B` |
| `BioMistral/BioMistral-7B` |
| `TsinghuaC3I/Llama-3.1-8B-UltraMedical` |
| `deepseek-ai/DeepSeek-R1-Distill-Llama-8B` |
| `Qwen/Qwen2.5-14B-Instruct` |
| `google/gemma-2-2b-it` |
| `google/gemma-2-9b-it` |
| `meta-llama/Llama-3.1-8B-Instruct` |
| `meta-llama/Llama-3.2-3B-Instruct` |
| `Qwen/Qwen2.5-7B-Instruct` |
| `Qwen/Qwen2.5-3B-Instruct` |{{< /table-caption >}}
> ğŸ”¼ í‘œ 6ì€ MedHallu ë°ì´í„°ì…‹ ìƒì„±ì— ì‚¬ìš©ëœ ì»´í“¨íŒ… ìì›ê³¼ ì¸í”„ë¼ì— ëŒ€í•œ ì„¸ë¶€ ì •ë³´ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.  ì—¬ê¸°ì—ëŠ” ìƒì„± ëª¨ë¸(Qwen2.5-14B)ì˜ ì»´í“¨íŒ… ì‹œê°„(26.5ì‹œê°„), ì‚¬ìš©ëœ GPU í•˜ë“œì›¨ì–´(4ê°œì˜ NVIDIA RTX A6000), ìƒì„±ëœ ë°ì´í„°ì…‹ì˜ í¬ê¸°(10,000ê°œ ìƒ˜í”Œ) ë“±ì´ í¬í•¨ë©ë‹ˆë‹¤.  ì¶”ê°€ì ìœ¼ë¡œ, ì •í™•ë„ ê²€ì¦ì„ ìœ„í•´ ì‚¬ìš©ëœ ì¶”ê°€ ëª¨ë¸(Gemma2-9B, Qwen2.5-7B, GPT4omini)ì˜ ë§¤ê°œë³€ìˆ˜ ìˆ˜ë„ ëª…ì‹œë˜ì–´ ìˆìŠµë‹ˆë‹¤.  í•˜ì§€ë§Œ, ì‹¤ì œ ì„±ëŠ¥ ë²¤ì¹˜ë§ˆí‚¹ì„ ìœ„í•´ ì‚¬ìš©ëœ íŒë³„ ëª¨ë¸ë“¤ì€ í¬í•¨ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 6: Computational Budget and Infrastructure Details while generating MedHallu Dataset, not includes the discriminator models used in benchmarking.
> </details>

{{< table-caption >}}
| Question | Category of Hallucination | Ground Truth | Hallucinated Example | Difficulty |
|---|---|---|---|---|
| Do mitochondria play a role in remodelling lace plant leaves during programmed cell death? | Mechanism and Pathway Misattribution | This is the first report of mitochondria and chloroplasts moving on transvacuolar strands to form a ring structure surrounding the nucleus during developmental PCD. Also, for the first time, we have shown the feasibility for the use of CsA in a whole plant system. Overall, our findings implicate the mitochondria as playing a critical and early role in developmentally regulated PCD in the lace plant. | Mitochondria regulate the formation of perforations in lace plant leaves through the modulation of calcium channels and by activating specific proteases that degrade cellular structures, facilitating the PCD process. | Medium |
| Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful? | Misinterpretation of #Question# | Higher MCVs and AST/ALT ratios in ASH reflect the severity of underlying liver disease and do not differentiate NASH from ASH. Instead, these biomarkers might prove useful in guiding selection of patients for liver biopsy and in targeting therapy. | Routine laboratory markers, particularly mean corpuscular volume (MCV) and AST/ALT ratios, significantly aid in differentiating various types of nonalcoholic steatohepatitis (NASH). | Hard |
| Amblyopia: is visual loss permanent? | Incomplete Information | Older people with a history of amblyopia who develop visual loss in the previously normal eye can experience recovery of visual function in the amblyopic eye over a period of time. This recovery in visual function occurs in the wake of visual loss in the fellow eye and the improvement appears to be sustained. | Visual loss due to amblyopia is permanent unless treated with early intervention during childhood. | Hard |{{< /table-caption >}}
> ğŸ”¼ ì´ í‘œëŠ” ì‹¤í—˜ì— ì‚¬ìš©ëœ ì‚¬ì „ í›ˆë ¨ëœ ì–¸ì–´ ëª¨ë¸ë“¤ì˜ ëª©ë¡ê³¼ í•´ë‹¹ ëª¨ë¸ë“¤ì˜ í—ˆê¹…í˜ì´ìŠ¤(Hugging Face) ì´ë¦„ì„ ë³´ì—¬ì¤ë‹ˆë‹¤.  ë…¼ë¬¸ì˜ ì‹¤í—˜ ë¶€ë¶„ì—ì„œ ë‹¤ì–‘í•œ ëª¨ë¸ë“¤ì˜ ì„±ëŠ¥ì„ ë¹„êµ ë¶„ì„í•˜ëŠ” ë° ì‚¬ìš©ë˜ì—ˆìœ¼ë©°, ê° ëª¨ë¸ì˜ ì´ë¦„ê³¼ í—ˆê¹…í˜ì´ìŠ¤ì—ì„œ ì ‘ê·¼ ê°€ëŠ¥í•œ ê³ ìœ  ì‹ë³„ìë¥¼ ëª…í™•íˆ ì œì‹œí•˜ì—¬ ì¬í˜„ì„±ì„ ë†’ì…ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 7: List of pre-trained models with their huggingface names used in our experiments.
> </details>

{{< table-caption >}}
| Question: | Prognosis of well differentiated small hepatocellular carcinomaâ€“is well differentiated hepatocellular carcinoma clinically early cancer? |
|---|---| 
| Ground Truth Answer: | W-d HCCs were clinically demonstrated not to be early cancer, because there was no significant difference in disease free survival between the patients with w-d and l-d HCCs. |
| Cluster 1 (Fooling) |  1. W-d HCCs are indeed clinically early cancer, due to their smaller size and lower incidence of fibrous capsule formation. 
2. W-d HCCs were clinically demonstrated to be early cancer due to their smaller tumor size and lower incidence of fibrous capsule formation. 
3. Well-differentiated small hepatocellular carcinoma is indeed early cancer, due to its slow growth rate. 
4. Well-differentiated hepatocellular carcinoma is clinically early cancer due to its low aggressive nature. 
5. Well differentiated hepatocellular carcinoma appears to be clinically early cancer due to its low aggressiveness. |
| Cluster 2 (That didnâ€™t fool) | 1. Well-differentiated hepatocellular carcinoma (HCC) is clinically early cancer due to its high histological grade. 
2. Due to its high histological grade, well-differentiated hepatocellular carcinoma (HCC) is considered clinically early cancer. |
| Cluster 3 (Fooling) | 1. Well-differentiated hepatocellular carcinoma is indeed an early cancer, as it often lacks fibrous capsule formation. 
2. Well-differentiated hepatocellular carcinomas (HCCs) are clinically early cancers due to their low incidence of fibrous capsule formation. |{{< /table-caption >}}
> ğŸ”¼ í‘œ 8ì€ Gemma2-9B-it ëª¨ë¸ì„ ì‚¬ìš©í•˜ì—¬ ìƒì„±ëœ MedHallu ë°ì´í„°ì…‹ì˜ ì¼ë¶€(pqa_labeledì—ì„œ 1,000ê°œ ìƒ˜í”Œ)ì— ëŒ€í•œ ì„±ëŠ¥ í‰ê°€ ê²°ê³¼ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ë‹¤ì–‘í•œ ì–¸ì–´ ëª¨ë¸(LLM)ì— ëŒ€í•´ ë‘ ê°€ì§€ ì¡°ê±´(ì™¸ë¶€ ì§€ì‹ ì—†ìŒ, ì™¸ë¶€ ì§€ì‹ ìˆìŒ)ì—ì„œ ì „ì²´ F1 ì ìˆ˜, ì •ë°€ë„, Easy/Medium/Hard F1 ì ìˆ˜ ë“±ì˜ ì„±ëŠ¥ ì§€í‘œì— ëŒ€í•œ í‰ê·  Â± í‘œì¤€ í¸ì°¨ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ë§ˆì§€ë§‰ ì—´(Î” F1)ì€ ì§€ì‹ì´ ìˆì„ ë•Œì™€ ì—†ì„ ë•Œì˜ F1 ì ìˆ˜ ì°¨ì´ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ í‘œëŠ” ì™¸ë¶€ ì§€ì‹ì´ LLMì˜ ì˜í•™ì  í™˜ê° íƒì§€ ì„±ëŠ¥ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì„ ë¶„ì„í•˜ëŠ” ë° ë„ì›€ì´ ë©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 8: Medhallu data generated by Gemma2-9B-it (1,000 samples of pqa_labeled). Mean Â±plus-or-minus\pmÂ± standard deviation of performance metrics (Overall F1, Overall Precision, Easy/Medium/Hard F1) for various LLMs under two conditions: without and with external knowledge. The final column (Î”Î”\Deltaroman_Î” F1) shows the difference in F1 scores (with knowledge minus without knowledge).
> </details>

</details>




### Full paper

{{< gallery >}}
<img src="paper_images/1.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/2.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/3.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/4.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/5.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/6.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/7.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/8.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/9.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/10.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/11.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/12.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/13.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/14.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/15.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/16.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/17.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/18.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
{{< /gallery >}}